calendar
07 Oct, 2020
JHBP (CY) Holdings Limited (“Genor Biopharma” or the “Company”; stock code: 6998.HK), a commercial-ready biopharmaceutical company focusing on developing and commercializing oncology and autoimmune drugs, was successfully listed and commenced trading on the Main Board of The Stock Exchange of Hong Kong Limited (“SEHK”) at 9:00am today, with a board lot of 500 Shares each.
1678
calendar
05 Aug, 2020
SHANGHAI, China, August 5, 2020 -- Genor Biopharma Co. Inc announced that National Medical Products Administration (NMPA) has granted priority review status to its new drug application (NDA) for Geptanolimab, a PD-1 mAb, on July 28, 7 days after the NDA acceptance.
1653
calendar
21 Jul, 2020
SHANGHAI, China, July 21, 2020 -- Genor Biopharma Co. Inc, a pre-commercial stage biopharmaceutical company focused on developing and commercializing oncology and autoimmune therapeutics, announced that the new drug application (NDA) for Geptanolimab, a novel PD-1 mAb drug candidate, has been accepted by the National Medical Products Administration (“NMPA”) for the treatment of Peripheral T cell Lymphoma (PTCL).
1646
calendar
29 Apr, 2020
SHANGHAI, China, April. 29, 2020 -- Genor Biopharma Co. Inc, a pre-commercial stage biopharmaceutical company focused on developing and commercializing immune-oncology therapeutics, today presented preliminary clinical data of two studies on its investigational PD-1 inhibitor Geptanolimab (GB226) at the 111st American Association for Cancer Research (AACR) Annual Meeting. Dr. SHI Yuankai orally presented the data on PTCL at the clinical trials plenary session on April. 28 (EDT).
1398
calendar
14 Apr, 2020
SHANGHAI, China, April. 14, 2020 -- Genor Biopharma Co. Inc, a pre-commercial stage biopharmaceutical company focused on developing and commercializing immune-oncology therapeutics, today announced that the preliminary clinical data on its investigational PD-1 inhibitor Geptanolimab would be presented at the 111st American Association for Cancer Research (AACR) Annual meeting. Among which the data on PTCL will be orally presented by Dr. Shi Yuankai at online annual meeting on April. 28 at the clinical trials plenary sessions.
1275